KalVista Pharmaceuticals - Public Comps and Valuation Multiples

KalVista Pharmaceuticals Overview

About KalVista Pharmaceuticals

KalVista Pharmaceuticals Inc is a pharmaceutical company developing and delivering oral therapies for individuals affected by rare diseases with unmet needs. The company applies its knowledge in the kallikrein-kinin system (KKS) and oral drug discovery to develop small-molecule protease inhibitor medicines to address the needs of patients with diseases driven by plasma kallikrein and Factor XIIa. Its FDA-approved product EKTERLY (sebetralstat) is a novel, orally delivered, small-molecule plasma kallikrein inhibitor for the treatment of acute attacks of hereditary angioedema (HAE) in adult and pediatric patients aged twelve years and older.

Founded

2004

HQ

Employees

270

Website

kalvista.com

Sectors

Drug Development & Therapeutics
Small Molecules
BioTech
DeepTech

Financials

LTM Revenue $12.7M

Last FY EBITDA -$173M

EV

$375M

Valuation Multiples

Multiples.vc

Valuation Multiples for 15K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

Browse Valuation Multiples

KalVista Pharmaceuticals Financials

As of September 2025, KalVista Pharmaceuticals reported last 12-month revenue of $12.7M.

In the same period, KalVista Pharmaceuticals generated $11.2M in LTM gross profit and -$176M in net income.

See KalVista Pharmaceuticals valuation multiples based on analyst estimates

KalVista Pharmaceuticals P&L

In the most recent fiscal year, KalVista Pharmaceuticals reported EBITDA of -$173M.

KalVista Pharmaceuticals expects next 12-month revenue of XXX and NTM EBITDA of XXX

See KalVista Pharmaceuticals valuation multiples based on analyst estimates

	LTM	NTM	Last FY	FY 2025	FY 2026	FY 2027
Revenue	$12.7M	XXX	n/a	XXX	XXX	XXX
Gross Profit	$11.2M	XXX	n/a	XXX	XXX	XXX
Gross Margin	88%	XXX	n/a	XXX	XXX	XXX
EBITDA	n/a	XXX	-$173M	XXX	XXX	XXX
EBITDA Margin	n/a	XXX	n/a	XXX	XXX	XXX
EBIT	-$181M	XXX	-$183M	XXX	XXX	XXX
EBIT Margin	-1426%	XXX	n/a	XXX	XXX	XXX
Net Profit	-$176M	XXX	-$183M	XXX	XXX	XXX
Net Margin	-1387%	XXX	n/a	XXX	XXX	XXX
Net Debt	XXX	XXX	n/a	XXX	XXX	XXX

Financial data powered by Morningstar, Inc.

.seo-only-financials-wrapper { position: static; left: auto; width: auto; height: auto; overflow: visible; }

Financial performance metrics for KalVista Pharmaceuticals including revenue, profitability, and margin analysis across different time periods. The company reported last twelve months revenue of $12.7M.
Financial Metric	Last Twelve Months (LTM)	Next Twelve Months (NTM)	Most Recent Fiscal Year	Current Fiscal Year (2025)	Next Fiscal Year (2026)	Two Years Forward (2027)
Total Revenue	$12.7M	Analyst estimates available to subscribers	n/a	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Gross Profit	$11.2M	Analyst estimates available to subscribers	n/a	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Gross Profit Margin	88.3% gross margin	Analyst estimates available to subscribers	n/a	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBITDA (Earnings Before Interest, Taxes, Depreciation, Amortization)	n/a	Analyst estimates available to subscribers	-$173M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBITDA Margin	n/a	Analyst estimates available to subscribers	n/a	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBIT (Earnings Before Interest and Taxes)	-$181M	Analyst estimates available to subscribers	-$183M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBIT Margin	-1426.3% EBIT margin	Analyst estimates available to subscribers	n/a	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Income (Net Profit)	-$176M	Analyst estimates available to subscribers	-$183M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Profit Margin	-1387.3% net profit margin	Analyst estimates available to subscribers	n/a	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Debt Position	Detailed debt information available to subscribers	Detailed debt information available to subscribers	n/a	Detailed debt information available to subscribers	Detailed debt information available to subscribers	Detailed debt information available to subscribers

Financial Performance Summary for KalVista Pharmaceuticals

This financial data table provides comprehensive performance metrics for KalVista Pharmaceuticals, a company based in United States of America. The metrics include revenue, profitability measures, and operational efficiency indicators across multiple time periods.

Recent Performance Highlights

KalVista Pharmaceuticals generated $12.7M in revenue over the last twelve months.
Gross profit for the last twelve months was $11.2M.
Net income over the last twelve months reached -$176M.

Fiscal Year Performance

Fiscal year EBITDA was -$173M.

This financial data is sourced from Morningstar, Inc. and represents the most recent available information for KalVista Pharmaceuticals. Forward-looking estimates and detailed financial projections are available through our premium subscription service.

KalVista Pharmaceuticals Stock Performance

KalVista Pharmaceuticals has current market cap of $561M, and EV of $375M.

Market Cap Evolution

KalVista Pharmaceuticals Stock Data

As of October 17, 2025, KalVista Pharmaceuticals's stock price is $11.

See KalVista Pharmaceuticals trading valuation data

EV	Market Cap	Price 1D	Price 1M	Price 3M	Price 12M	EPS
$375M	$561M	XXX	XXX	XXX	XXX	$-3.51

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Start Free Trial

KalVista Pharmaceuticals Valuation Multiples

KalVista Pharmaceuticals's trades at n/a EV/Revenue multiple, and -2.2x EV/EBITDA.

See valuation multiples for KalVista Pharmaceuticals and 15K+ public comps

KalVista Pharmaceuticals Financial Valuation Multiples

As of October 17, 2025, KalVista Pharmaceuticals has market cap of $561M and EV of $375M.

Equity research analysts estimate KalVista Pharmaceuticals's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

KalVista Pharmaceuticals has a P/E ratio of -3.2x.

	LTM	NTM	Last FY	FY 2025	FY 2026	FY 2027
Market cap (current)	$561M	XXX	$561M	XXX	XXX	XXX
EV (current)	$375M	XXX	$375M	XXX	XXX	XXX
EV/Revenue	29.6x	XXX	n/a	XXX	XXX	XXX
EV/EBITDA	n/a	XXX	-2.2x	XXX	XXX	XXX
EV/EBIT	-2.1x	XXX	-2.1x	XXX	XXX	XXX
EV/Gross Profit	33.6x	XXX	n/a	XXX	XXX	XXX
P/E	-3.2x	XXX	-3.1x	XXX	XXX	XXX
EV/FCF	n/a	XXX	-2.4x	XXX	XXX	XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get KalVista Pharmaceuticals Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Start Free Trial

KalVista Pharmaceuticals Margins & Growth Rates

KalVista Pharmaceuticals's last 12 month revenue growth is 713%

KalVista Pharmaceuticals's revenue per employee in the last FY averaged n/a, while opex per employee averaged $0.7M for the same period.

KalVista Pharmaceuticals's rule of 40 is unknown (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

KalVista Pharmaceuticals's rule of X is unknown (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

See operational valuation multiples for KalVista Pharmaceuticals and other 15K+ public comps

KalVista Pharmaceuticals Operational Valuation Multiples

	LTM	NTM	Last FY	FY 2025	FY 2026	FY 2027
Revenue Growth	713%	XXX	n/a	XXX	XXX	XXX
EBITDA Margin	n/a	XXX	n/a	XXX	XXX	XXX
EBITDA Growth	n/a	XXX	n/a	XXX	XXX	XXX
Rule of 40	n/a	XXX	n/a	XXX	XXX	XXX
Bessemer Rule of X	XXX	XXX	n/a	XXX	XXX	XXX
Revenue per Employee	XXX	XXX	n/a	XXX	XXX	XXX
Opex per Employee	XXX	XXX	$0.7M	XXX	XXX	XXX
S&M Expenses to Revenue	XXX	XXX	n/a	XXX	XXX	XXX
G&A Expenses to Revenue	XXX	XXX	n/a	XXX	XXX	XXX
R&D Expenses to Revenue	XXX	XXX	n/a	XXX	XXX	XXX
Opex to Revenue	XXX	XXX	n/a	XXX	XXX	XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics

Pharma Analytics

Private Equity

ERP Software

Developer Tools

Consumer SaaS

Streaming Platforms

Explore Valuation Multiples by Industry

Start Free Trial